Cellular Therapy with Autologous Mesenchymal Stromal Cells in Patients with Drug Resistant Pulmonary Tuberculosis

Q4 Medicine

Tuberculosis and Lung Diseases Pub Date : 2023-12-25 DOI:10.58838/2075-1230-2023-101-6-74-80

V. Solodovnikova, A. E. Skryagin, Y. I. Isaykina, D. A. Klimuk, G. L. Gurevich, E. M. Skryagina

{"title":"Cellular Therapy with Autologous Mesenchymal Stromal Cells in Patients with Drug Resistant Pulmonary Tuberculosis","authors":"V. Solodovnikova, A. E. Skryagin, Y. I. Isaykina, D. A. Klimuk, G. L. Gurevich, E. M. Skryagina","doi":"10.58838/2075-1230-2023-101-6-74-80","DOIUrl":null,"url":null,"abstract":"The objective: to evaluate the effectiveness of treatment with autologous mesenchymal stromal cells (MSCs) in patients with drug resistant pulmonary tuberculosis (DR TB).Subjects and Methods. 120 patients with drug resistant tuberculosis aged 18 to 61 years old were enrolled in the study. They all were treated at the Republican Scientific and Practical Center of Pulmonology and Phthisiology from 2009 to 2018. Against the background of anti-tuberculosis treatment, patients (60 people) from Main Group (MG) underwent bone marrow sampling and then intravenous administration of autologous MSCs.Results. The average dose of administered cells was 1x106 per kg of the patient body weight. The average duration of MSC cultivation made 35 days. Treatment effectiveness in MG made 90% versus 71% in Control Group (CG). All patients who were successfully cured of tuberculosis (TB) using autologous MSCs had no tuberculosis relapses during 5 years of follow-up. In Control Group, 8 (19%) cases of relapse were reported. In Main Group versus Comparison Group, the rates indicating healing of cavities and absence of relapse are statistically significantly better.Conclusion. The use of autologous MSCs in patients with drug resistant tuberculosis has shown its high effectiveness.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":"46 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis and Lung Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.58838/2075-1230-2023-101-6-74-80","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The objective: to evaluate the effectiveness of treatment with autologous mesenchymal stromal cells (MSCs) in patients with drug resistant pulmonary tuberculosis (DR TB).Subjects and Methods. 120 patients with drug resistant tuberculosis aged 18 to 61 years old were enrolled in the study. They all were treated at the Republican Scientific and Practical Center of Pulmonology and Phthisiology from 2009 to 2018. Against the background of anti-tuberculosis treatment, patients (60 people) from Main Group (MG) underwent bone marrow sampling and then intravenous administration of autologous MSCs.Results. The average dose of administered cells was 1x106 per kg of the patient body weight. The average duration of MSC cultivation made 35 days. Treatment effectiveness in MG made 90% versus 71% in Control Group (CG). All patients who were successfully cured of tuberculosis (TB) using autologous MSCs had no tuberculosis relapses during 5 years of follow-up. In Control Group, 8 (19%) cases of relapse were reported. In Main Group versus Comparison Group, the rates indicating healing of cavities and absence of relapse are statistically significantly better.Conclusion. The use of autologous MSCs in patients with drug resistant tuberculosis has shown its high effectiveness.

查看原文本刊更多论文

用自体间充质基质细胞为耐药肺结核患者提供细胞疗法

目的：评估自体间充质干细胞（MSCs）治疗耐药性肺结核（DR TB）患者的效果。120名年龄在18至61岁之间的耐药性肺结核患者参与了研究。他们均于 2009 年至 2018 年期间在共和国肺科和咽喉科科学实践中心接受治疗。在抗结核治疗的背景下，主组（MG）患者（60 人）接受了骨髓采样，然后静脉注射自体间充质干细胞。给药细胞的平均剂量为每公斤患者体重 1x106。间充质干细胞的平均培养时间为 35 天。MG组的治疗有效率为90%，而对照组（CG）为71%。所有使用自体间充质干细胞成功治愈肺结核（TB）的患者在 5 年的随访中均未复发肺结核。对照组有 8 例（19%）复发。主要组与对比组相比，龋齿愈合率和无复发率在统计学上明显更高。自体间充质干细胞在耐药性肺结核患者中的应用已显示出其高度有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tuberculosis and Lung Diseases Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： The Journal is aimed for professional development of researchers, doctors, teachers of medical universities and training institutions. The Journal focuses on the presentation of results of research, case studies, issues of differential diagnostics and treatment in the phthisiologist’s practice, national programs on tuberculosis control in the Russian Federation, WHO strategies, discussion of prevention issues to stop transmission of TB/HIVco-infection, and extrapulmonary tuberculosis.